share_log

424B3: Prospectus

424B3: Prospectus

424B3：募资说明书
美股sec公告 ·  06/27 08:22
Moomoo AI 已提取核心信息
NeuroSense Therapeutics has filed a prospectus supplement on June 27, 2024, to update and amend its previous prospectus dated May 22, 2024. This supplement includes information from the company's Report on Form 6-K submitted to the SEC on the same date. The supplement details amendments to warrants issued to an institutional investor, extending the termination date of warrants from 2023 and 2024 to October 12, 2029. The amendments also adjust the 'Redemption Right' in the 2023 Warrant. NeuroSense Therapeutics' ordinary shares and warrants are traded on the Nasdaq under the symbols 'NRSN' and 'NRSNW,' with closing prices on June 26, 2024, at $0.85 and $0.18 respectively. The company highlights the high degree of risk involved in investing in its securities and refers to the 'Risk Factors' section of the Prospectus for more details. The SEC, Israeli Securities Authority, nor any state securities commission has approved or disapproved the securities, nor have they confirmed the completeness or truthfulness of the Prospectus or this supplement.
NeuroSense Therapeutics has filed a prospectus supplement on June 27, 2024, to update and amend its previous prospectus dated May 22, 2024. This supplement includes information from the company's Report on Form 6-K submitted to the SEC on the same date. The supplement details amendments to warrants issued to an institutional investor, extending the termination date of warrants from 2023 and 2024 to October 12, 2029. The amendments also adjust the 'Redemption Right' in the 2023 Warrant. NeuroSense Therapeutics' ordinary shares and warrants are traded on the Nasdaq under the symbols 'NRSN' and 'NRSNW,' with closing prices on June 26, 2024, at $0.85 and $0.18 respectively. The company highlights the high degree of risk involved in investing in its securities and refers to the 'Risk Factors' section of the Prospectus for more details. The SEC, Israeli Securities Authority, nor any state securities commission has approved or disapproved the securities, nor have they confirmed the completeness or truthfulness of the Prospectus or this supplement.
NeuroSense Therapeutics于2024年6月27日提交了一份招股说明书补充，以更新其于2024年5月22日发布的先前招股说明书。此补充包含公司在同一日期提交给SEC的6-K表格中的信息。补充详细说明了对发行给机构投资者的认股权证的修改，将认购期限从2023年和2024年延长至2029年10月12日。修改还调整了2023年认股权证的“赎回权”。NeuroSense Therapeutics的普通股和认股权证在纳斯达克上交易，代码分别为“NRSN”和“NRSNW”，截至2024年6月26日收盘价分别为0.85美元和0.18美元。公司强调投资其证券存在高风险，并参考招股说明书的“风险因素”部分了解更多详情。SEC、以色列证券监管机构或任何州证券委员会均未批准或不批准证券，也未确认招股说明书或本补充说明书的完整性或真实性。
NeuroSense Therapeutics于2024年6月27日提交了一份招股说明书补充，以更新其于2024年5月22日发布的先前招股说明书。此补充包含公司在同一日期提交给SEC的6-K表格中的信息。补充详细说明了对发行给机构投资者的认股权证的修改，将认购期限从2023年和2024年延长至2029年10月12日。修改还调整了2023年认股权证的“赎回权”。NeuroSense Therapeutics的普通股和认股权证在纳斯达克上交易，代码分别为“NRSN”和“NRSNW”，截至2024年6月26日收盘价分别为0.85美元和0.18美元。公司强调投资其证券存在高风险，并参考招股说明书的“风险因素”部分了解更多详情。SEC、以色列证券监管机构或任何州证券委员会均未批准或不批准证券，也未确认招股说明书或本补充说明书的完整性或真实性。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息